Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

European approvals for J&J cancer treatments

EC passes new Dacogen indications and backs subcutaneous Velcade

Ten pharma firms team up on new drug development

Joint venture to take on some of the key challenges and bottlenecks in drug development

Amgen poaches J&J’s Ray Jordan for corporate affairs post

He joins on October, 1 with a strategic communications remit

- PMLiVE

J&J signs $1.1bn deal with Genmab for cancer antibody

Licenses daratumumab in development for multiple myeloma

Amgen-Takeda’s ganitumab fails in pancreatic cancer study

Interim analysis shows no improvement in overall survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links